Screener
Royalty Pharma RPRX Income Tax
Income Tax at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:02 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001802768-26-000015
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Other non-operating expenses, net | 1,496 | 1,543 | 3,697 | 4,604 |
| Total other expense, net | 51,633 | 117,164 | 146,415 | 216,912 |
| Consolidated net income before tax | 81,486 | 92,635 | 549,741 | 527,068 |
| Income tax expense | — | — | — | — |
| Consolidated net income | 81,486 | 92,635 | 549,741 | 527,068 |
| Net income attributable to non-controlling interests | 63,603 | 60,459 | 237,169 | 255,543 |
| Net income attributable to Royalty Pharma plc | $17,883 | $32,176 | $312,572 | $271,525 |
| Earnings per Class A ordinary share: |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Royalty Pharma's income tax?
- Royalty Pharma (RPRX) reported income tax of $0 in Q2 2026.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about Royalty Pharma's income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude